Aim. To evaluate clinical-economical effectiveness of direct oral anticoagulants (DOAC) dabigatran, rivaroxaban, and apixaban in comparison with warfarin in atrial fibrillation (AF) therapy.Materials and Methods. Mathematical modeling (tree derivation of solutions) on a temporary 5-year horizon from the medical healthcare system perspective. Methods of clinical-economic analysis: analysis “cost-effectiveness”, “budget impact”, and “the analysis of unseized opportunities”.Results. Total direct costs (DC) were lower by 10.3% when dabigatran was used, by 5.2%, when rivaroxaban was used, and by 10.9%, when apixaban was used in comparison with warfarin. The most significant difference was observed due to different cost of therapy for bleeding co...
BACKGROUND: Dabigatran 150 mg BID (D150) and rivaroxaban 20 mg (R20) are indicated for the preventio...
Background and Purpose-Direct oral anticoagulants (DOACs) are safer, at least equally efficacious, a...
Objectives. Determine the optimal, licensed, first-line anticoagulant for prevention of ischemic str...
AbstractObjectivesThe primary objective was to assess the cost-effectiveness of new oral anticoagula...
Background. Dabigatran is an oral anticoagulant direct thrombin inhibitor recently registered in Sou...
<p>Atrial fibrillation (AF) is a risk factor for thromboembolic complications, requiring administrat...
Objective: new oral anticoagulants (apixaban, dabigatran and rivaroxaban) are the newest advance for...
Health care resources available for medical procedures, including pharmaceuticals, are limited world...
Background and objective Non-valvular atrial fibrillation (NVAF) increases the risk of systemic thr...
OBJECTIVES: Our objectives were to investigate the cost effectiveness of apixaban, rivaroxaban, and ...
Objective: The primary objective of this study was to estimate the long-term cost-effectiveness of s...
Objectives: To develop a state-transition model evaluating the cost-effectiveness of all antithrombo...
Warfarin and new oral anticoagulants are effective in reducing stroke in atrial fibrillation; howeve...
The Author(s) 2014. This article is published with open access at Springerlink.com Background Atrial...
IntroductionThe Apixaban for the Reduction in Stroke and Other Thromboembolic Events in Atrial Fibri...
BACKGROUND: Dabigatran 150 mg BID (D150) and rivaroxaban 20 mg (R20) are indicated for the preventio...
Background and Purpose-Direct oral anticoagulants (DOACs) are safer, at least equally efficacious, a...
Objectives. Determine the optimal, licensed, first-line anticoagulant for prevention of ischemic str...
AbstractObjectivesThe primary objective was to assess the cost-effectiveness of new oral anticoagula...
Background. Dabigatran is an oral anticoagulant direct thrombin inhibitor recently registered in Sou...
<p>Atrial fibrillation (AF) is a risk factor for thromboembolic complications, requiring administrat...
Objective: new oral anticoagulants (apixaban, dabigatran and rivaroxaban) are the newest advance for...
Health care resources available for medical procedures, including pharmaceuticals, are limited world...
Background and objective Non-valvular atrial fibrillation (NVAF) increases the risk of systemic thr...
OBJECTIVES: Our objectives were to investigate the cost effectiveness of apixaban, rivaroxaban, and ...
Objective: The primary objective of this study was to estimate the long-term cost-effectiveness of s...
Objectives: To develop a state-transition model evaluating the cost-effectiveness of all antithrombo...
Warfarin and new oral anticoagulants are effective in reducing stroke in atrial fibrillation; howeve...
The Author(s) 2014. This article is published with open access at Springerlink.com Background Atrial...
IntroductionThe Apixaban for the Reduction in Stroke and Other Thromboembolic Events in Atrial Fibri...
BACKGROUND: Dabigatran 150 mg BID (D150) and rivaroxaban 20 mg (R20) are indicated for the preventio...
Background and Purpose-Direct oral anticoagulants (DOACs) are safer, at least equally efficacious, a...
Objectives. Determine the optimal, licensed, first-line anticoagulant for prevention of ischemic str...